Kiniksa Pharmaceuticals International Plc (KNSA) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)


Kiniksa Pharmaceuticals International Plc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KNSA Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change 58.12 %
Seq. Revenue Change 17.39 %
Revenue In Millions $285.97
Gross Profit Margin 90.29 %
Gross Profit Margin Total Ranking # 369
Gross Profit In Millions $258.21
Y / Y Gross Profit Change 60.78 %
Seq. Gross Profit Change -


Commenting Third Quarter 2026 Gross Profit Margin
Kiniksa Pharmaceuticals International Plc achieved Gross Profit of $258 millions compare to Gross Loss of $0.00 millions recorded in the previous quarter. Revenue increased by 17.39 % Company accomplished above average Gross Profit Margin with 90.29 %.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 37 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 369, from total ranking in the previous quarter at 411.
Learn about Gross Margin
KNSA's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 38
Healthcare Sector # 58
Overall # 366

Gross Profit Margin Statistics
High Average Low
93 % 85.79 % 67.99 %
(Sep 30 2022)   (Jun 30 2021)


KNSA Gross Income Trends • More of KNSA's Profitabilty Ratios • KNSA Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
KNSA's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
KNSA's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for KNSA's Competitors
Gross Profit Margin Profit Margin for Kiniksa Pharmaceuticals International Plc's Suppliers
Gross Profit Margin Profit Margin for KNSA's Customers

You may also want to know
KNSA's Annual Growth Rates KNSA's Profitability Ratios KNSA's Asset Turnover Ratio KNSA's Dividend Growth
KNSA's Roe KNSA's Valuation Ratios KNSA's Financial Strength Ratios KNSA's Gross Profit Growth
KNSA's Roa KNSA's Inventory Turnover Ratio KNSA's Growth Rates KNSA's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Protagonist Therapeutics inc   99.60 %$ 273.310  Millions$ 274.410  Millions
Lexicon Pharmaceuticals Inc   99.30 %$ 11.171  Millions$ 11.250  Millions
Verastem Inc   98.84 %$ 23.733  Millions$ 24.012  Millions
Travere Therapeutics Inc   98.72 %$ 221.696  Millions$ 224.563  Millions
Adc Therapeutics Sa  98.67 %$ 21.428  Millions$ 21.716  Millions
Corcept Therapeutics Inc  98.65 %$ 335.864  Millions$ 340.472  Millions
Ionis Pharmaceuticals Inc   98.63 %$ 239.399  Millions$ 242.721  Millions
Kura Oncology Inc   98.38 %$ 22.468  Millions$ 22.839  Millions
Ardelyx inc   96.44 %$ 123.116  Millions$ 127.655  Millions
Uniqure N v   95.46 %$ 4.960  Millions$ 5.196  Millions
Agios Pharmaceuticals Inc   95.44 %$ 52.860  Millions$ 55.385  Millions
Zevra Therapeutics Inc   95.25 %$ 35.962  Millions$ 37.756  Millions
Bridgebio Pharma Inc   94.21 %$ 332.721  Millions$ 353.171  Millions
Gyre Therapeutics Inc   94.09 %$ 30.987  Millions$ 32.934  Millions
Vanda Pharmaceuticals Inc   94.05 %$ 65.663  Millions$ 69.815  Millions
Axsome Therapeutics Inc   93.14 %$ 241.887  Millions$ 259.691  Millions
Tonix Pharmaceuticals Holding Corp   92.74 %$ 15.982  Millions$ 17.234  Millions
Urogen Pharma Ltd   91.57 %$ 81.499  Millions$ 89.001  Millions
Arcutis Biotherapeutics Inc   91.34 %$ 131.459  Millions$ 143.919  Millions
Roivant Sciences Ltd   90.47 %$ 31.774  Millions$ 35.121  Millions
Kiniksa Pharmaceuticals International Plc  90.29 %$ 258.211  Millions$ 285.970  Millions
Aurinia Pharmaceuticals Inc   90.08 %$ 75.393  Millions$ 83.699  Millions
Acadia Pharmaceuticals Inc   89.75 %$ 307.201  Millions$ 342.291  Millions
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Ocular Therapeutix Inc   88.70 %$ 11.419  Millions$ 12.874  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions
United Therapeutics Corporation  88.10 %$ 733.400  Millions$ 832.500  Millions
Supernus Pharmaceuticals inc   88.09 %$ 199.753  Millions$ 226.771  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.